Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SAN FRANCISCO, May 07, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Solid Biosciences, Inc. (NASDAQ:SLDB) of the May 29, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
